⌘K
Loading ticker…
As of 2026-08-24, Pelthos Therapeutics Inc. (PTHS) has a 3-month relative strength percentile of 48 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.7%, relative volume 1.77×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PTHS is in a stage 1 base, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -2.6% / 2.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
PTHS is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $2M notional.
Held by 2 ETFs · $2M across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $2M | — |
| VXFVanguard Extended Market ETF | 0.00% | $273K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PTHS Jan avg: -22.52% median: -22.52% win: 0% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Feb avg: 9.74% median: 9.74% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Mar avg: -20.30% median: -20.30% win: 0% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Apr avg: 18.99% median: 18.99% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS May avg: 5.88% median: 5.88% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Jun avg: 6.76% median: 6.76% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Jul avg: 14.80% median: 14.80% win: 100% σ: 18.93% n: 2 2025-07-03 → 2026-07-31 | PTHS Aug avg: 11.82% median: 11.82% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 (current) | PTHS Sep avg: 18.39% median: 18.39% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Oct avg: 17.86% median: 17.86% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Nov avg: -13.94% median: -13.94% win: 0% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 | PTHS Dec avg: 9.16% median: 9.16% win: 100% σ: 0.00% n: 1 2025-07-03 → 2026-07-31 |